넥센티스 테크놀로지스NXTS 주가

[8-K] 중대 사건 — 8-K

Nexentis Subsidiary MitoCareX Hits First Drug‑Discovery Milestone With Optimized Molecule

Nexentis Technologies Inc. (NASDAQ:NXTS) ("Nexentis" or the "Company"), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly

Nexentis Announces MitoCareX Bio Achieves Key R&D Milestone, Generating a Substantially Improved Hit Molecule on the Path to Pre-Clinical Development

Ness Ziona, Israel, May 18, 2026 -- Nexentis Technologies Inc. , a drug discovery company that also invests in solar energy assets based on the RTB business model, today announced that its wholly...

[10-Q] 분기 실적 — 10-Q

Nexentis Technologies Announces Optimization of Hit Molecule at MitoCareX Bio Representing Key Drug Discovery Milestone

MITOLINE®-Powered Platform Delivers Optimized Hit Molecule, Strengthening the Foundation for Future Pre-Clinical and Commercial Development Neve Yarak, Israel, May 13, 2026 -- Nexentis...

Nexentis Technologies' Subsidiary Receives U.S. Patent And Trademark Office Official Trademark Registration For Its MITOLINE Algorithm Platform

Nexentis Technologies Inc. (NASDAQ:NXTS), ("Nexentis" or the "Company"), a drug discovery company that is also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its

[8-K] 중대 사건 — 8-K

[EFFECT] EFFECT

[CORRESP] CORRESP

[UPLOAD] UPLOAD